

October 28, 2005

Mediceo Paltac Holdings Co., Ltd.

Representative Director, President and CEO: Sadatake Kumakura

Code number: 7459 (First Section, Tokyo Stock Exchange)

Contact: Kikuo Miki, Managing Executive Officer
and Manager of Corporate Communication Office

Tel.: +81-3- 3517-5171

Notice of Revisions to Interim Performance Forecasts

October 28, 2005 – Mediceo Paltac Holdings Co., Ltd. (“Mediceo Paltac”) has revised its performance forecasts for the interim period of the fiscal year ending March 31, 2006 (April 1, 2005 to September 30, 2005), which were disclosed at the time of its announcement of business results on May 13, 2005, as follows.

1. Revisions to Performance Forecasts for the Interim Period

(April 1, 2005 - September 30, 2005)

(1) Consolidated

(Millions of yen; %)

	Net sales	Ordinary income	Net income
Previous forecast (A)	832,000	8,400	6,100
Revised forecast (B)	850,000	11,400	9,000
Amount of change (B-A)	18,000	3,000	2,900
Percentage change (%)	2.2	35.7	47.5
Results for the interim period of the fiscal year ended March 31, 2005	814,869	12,332	6,869

(2) Non-consolidated

(Millions of yen; %)

	Net sales	Ordinary income	Net income
Previous forecast (A)	727,000	3,500	1,800
Revised forecast (B)	744,000	4,100	2,400
Amount of change (B-A)	17,000	600	600
Percentage change (%)	2.3	17.1	33.3
Results for the interim period of the fiscal year ended March 31, 2005	614,397	4,799	2,233

2. Reasons for the Revision to the Performance Forecasts (Announced May 13, 2005)

During the interim period ended September 30, 2005, the market for ethical drugs, which are the Mediceo Paltac Group's core business, displayed moderate growth overall, due to factors including prolonged outbreaks of influenza and pollen allergies, resulting in greater demand for related medicines, as well as increased sales of drugs for lifestyle-related diseases.

Amid these conditions, the Mediceo Paltac Group promoted integrated sales policies for ethical drugs while working to secure adequate profit. In addition, the Group has continued to work to reduce or contain selling, general and administrative expenses by cutting costs and improving operating efficiency.

As a result of these factors, both the consolidated and non-consolidated interim period performance forecasts for net sales, ordinary income and net income have been revised upward.

3. Revision of Performance Forecasts for the Full Fiscal Year (Announced May 13, 2005)

Mediceo Paltac is currently revising its forecasts for consolidated and non-consolidated results for the full fiscal year (April 1, 2005 to March 31, 2006), and plans to announce the revisions at the time of the announcement of interim results scheduled for November 11, 2005.

#